PDCD1 and neoplasm: Therefore, anti-PD-1/PD-L1 inhibitors are able to induce durable tumor regression and represent a unique therapeutic strategy for patients with advanced cancers (Couzin-Frankel, 2013; Mahoney et al., 2015; Ribas et al., 2016; Yaghoubi et al., 2019).